Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

SIMPLE SUMMARY: The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through direct effects on tumor cells, but also by its effects on T-cell immunity through depletion of CD38(+) immune suppressor cells. We hypothesized that combining daratumumab with modulators of...

Descripción completa

Detalles Bibliográficos
Autores principales: Verkleij, Christie P. M., Jhatakia, Amy, Broekmans, Marloes E. C., Frerichs, Kristine A., Zweegman, Sonja, Mutis, Tuna, Bezman, Natalie A., van de Donk, Niels W. C. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764511/
https://www.ncbi.nlm.nih.gov/pubmed/33321969
http://dx.doi.org/10.3390/cancers12123713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764511/
https://www.ncbi.nlm.nih.gov/pubmed/33321969
http://dx.doi.org/10.3390/cancers12123713

Ejemplares similares